


# متاآنالیز شبکه ای : درک مفاهیم و کاربرد عملی



**دکتر محمد حیدری**

استادیار اپیدمیولوژی

گروه اپیدمیولوژی و آمار زیستی ، دانشکده پزشکی

دانشگاه علوم پزشکی ارومیه

۱۹ آذر ۱۴۰۲

ایمیل: [heidari.m@umsu.ac.ir](mailto:heidari.m@umsu.ac.ir)


# مشکل بزرگ پزشکی مدرن :



❑ وجود دریایی از داده ها و مقالات

❑ تفسیر نتایج متناقض

# قصه متاآنالیز:



- ❑ فهم اینکه تاثیر درمان های مختلف در شرایط متفاوت چگونه است
- ❑ یافتن اینکه چه وقت درمان نتیجه منفی دارد
- ❑ ترکیب حجم عظیمی از اطلاعات بصورت چیزی قابل استفاده
- ❑ شناخت کیفیت مطالعات مختلف
- ❑ بسیار مورد علاقه سیاستگذاران سلامت
- ❑ ارجاع خوردن بالا و بسیار تاثیرگذار

# David M. Eddy: آغاز متاآنالیز شبکه ای

## THE CONFIDENCE PROFILE METHOD: A BAYESIAN METHOD FOR ASSESSING HEALTH TECHNOLOGIES

DAVID M. EDDY

*Duke University, Durham, North Carolina*

(Received November 1986; revisions received September 1987, February 1988; accepted April 1988)

The Confidence Profile Method is a Bayesian method for adjusting and combining pieces of evidence to estimate parameters, such as the effect of health technologies on health outcomes. The information in each piece of evidence is captured in a likelihood function that gives the likelihood of the observed results of the evidence as a function of possible values of the parameter. A posterior distribution is calculated from Bayes formula as the product of the likelihood function and a prior distribution. Multiple pieces of evidence are incorporated by successive applications of Bayes' formula. Pieces of evidence are adjusted for biases to internal or external validity by modeling the biases and deriving "adjusted" likelihood functions that incorporate the models. Likelihood functions have been derived for one-, two- and multi-arm prospective studies;  $2 \times 2$ ,  $2 \times n$  and matched case-control studies, and cross-sectional studies. Biases that can be incorporated in likelihood functions include crossover in controlled trials, error in measurement outcomes, patient selection biases, differences in technologies, and differences in length of follow-up. Effect measures include differences of rates, ratios of rates, and odds ratios. The elements of the method are illustrated with an analysis of the effect of a thrombolytic agent on the difference in probability of 1-year survival after a heart attack.


The first step in the assessment of a health technology is to evaluate the existing evidence to estimate how the technology affects the magnitude or probability of important health outcomes—its bene-

fitive, which leaves it vulnerable to oversimplification, errors in reasoning, wishful thinking, and self-interest.

This paper introduces a Bayesian method for syn-



# تعداد مقالات نمایه شده در PUBMED با موضوع متاآنالیز شبکه ای



# نام های دیگر متاآنالیز شبکه ای: Network Meta Analysis

- Multiple treatments meta-analysis
- Mixed treatment comparisons

# فهم منطق متاآنالیز شبکه ای

□ اثر غیر مستقیم : Indirect Effect


□ اثر ترکیبی : Mixed Effect

# متاآنالیز دو به دو - pairwise




**سوال پژوهش:** آیا درمان A از درمان B بهتر است؟

# مشکل متاآنالیز دو به دو



آیا درمان A از درمان B بهتر است؟


# اما سوال واقعی چیست؟



□ کدامیک از درمان موجود بیش از بقیه موثر است؟


□ آیا درمان F از درمان B بهتر است؟

# منطق محاسبه مقایسه غیر مستقیم:



## مقایسه غیر مستقیم چیست؟


تخمین غیر مستقیم اثر درمان B در مقابل C از کارآزمایی‌هایی که A v B و A v C را مقایسه می‌کنند.




**Treatment effect BC** = Treatment effect AC - Treatment effect AB

**Variance BC** = variance AC + variance AB

# مثال : مقایسه اثر مداخلات مختلف در پوسیدگی دندان




# مثال : مقایسه اثر خمیردندان و ژل




$$\text{SMD} = -0.34 - (-0.19) = -0.15$$

Variance is -0.27 to -0.03


# استفاده از مقایسه مستقیم و غیر مستقیم:



# Indirect and mixed effects:



# اثر ترکیبی (مستقیم + غیر مستقیم) : دقت برآورد بالا




# فرمول محاسبه مقدار mixed و ویرایانس


$$\text{Mixed SMD} = \frac{\frac{\text{SMD}_{\text{Direct}}}{\text{var}(\text{SMD}_{\text{Direct}})} + \frac{\text{SMD}_{\text{Indirect}}}{\text{var}(\text{SMD}_{\text{Indirect}})}}{\frac{1}{\text{var}(\text{SMD}_{\text{Direct}})} + \frac{1}{\text{var}(\text{SMD}_{\text{Indirect}})}}$$

$$\text{var}(\text{Mixed SMD}) = \frac{1}{\frac{1}{\text{var}(\text{SMD}_{\text{Direct}})} + \frac{1}{\text{var}(\text{SMD}_{\text{Indirect}})}}$$


A




B



C




D



لوپ بسته

Indirect treatment comparison  
Open loop

Mixed treatment comparison  
Closed loop




Direct comparison

Indirect comparison

A

B

C



Direct comparison

Indirect comparison


A

B


C

# متاآنالیز شبکه ای : ترکیب متاآنالیزهای دو به دو


**A vs B**




**A vs C**




**C vs D**



**D vs E**






12/10/2023

Mohammad Heidari , Ph.D in Epidemiology, Urmia University of Medical Sciences


# مدل آماری متاآنالیز شبکه ای:

- Meta-analysis : a weighted regression with no covariates
- Network meta-analysis : a weighted regression with dummy variables for the treatments
- You should take into account correlations in multi-arm trials

# رتبه بندی مداخلات:



# مشکل معروف ترکیب سیب و پرتقال در متاآنالیز



Mohammad Heidari , Ph.D in  
Epidemiology, Urmia University of  
Medical Sciences

**Homogeneity** □ فرض عدم ناهمگنی در مقایسه های مستقیم دو به دو

Heterogeneity in Direct Comparison..... (Cochrane Q &  $I^2$ ) •


**Transitivity (similarity)** □ شرایط ایدآل کارآزمایی های بزرگ است که تمام مداخلات ممکن

تصادفی اجرا شوند . مشکل برآورد های مستقیم و غیر مستقیم

Clinical experts •

**Consistency (Coherence)** □ برابری برآورد مستقیم و غیر مستقیم

(Loop Specific & Cochrane Q for Total Network) •



# سنجش کیفیت شواهد :

Mohammad Heidari , Ph.D in  
Epidemiology, Urmia University of  
Medical Sciences

# Cochrane RoB 2.0 :Bias summary of included Randomized Controlled Trials

|                                                           | Agarwal R et al 2019 (AMBER) | Anker SD et al 2015 | Ash SR et al 2015 | Fishbane S et al 2019 (DIALIZE) | Packham DK et al 2014 | Peacock WF et al 2020 (ENERGIZE) | Pitt B et al 2011 (PEARL-HF) | Rafique Z et al 2020 | Weir MR et al 2014 (OPAL-HK) | Zannad F et al 2020 (HARMONIZE) |
|-----------------------------------------------------------|------------------------------|---------------------|-------------------|---------------------------------|-----------------------|----------------------------------|------------------------------|----------------------|------------------------------|---------------------------------|
| Random sequence generation (selection bias)               | +                            | +                   | +                 | ?                               | +                     | +                                | +                            | +                    | +                            | +                               |
| Allocation concealment (selection bias)                   | +                            | +                   | +                 | +                               | +                     | +                                | +                            | -                    | +                            | +                               |
| Blinding of participants and personnel (performance bias) | +                            | +                   | +                 | +                               | +                     | +                                | +                            | -                    | +                            | +                               |
| Blinding of outcome assessment (detection bias)           | +                            | +                   | +                 | +                               | +                     | +                                | +                            | ?                    | -                            | +                               |
| Incomplete outcome data (attrition bias)                  | +                            | +                   | +                 | +                               | +                     | -                                | +                            | -                    | +                            | -                               |
| Selective reporting (reporting bias)                      | +                            | +                   | +                 | +                               | +                     | -                                | +                            | +                    | +                            | -                               |
| Other bias                                                | ?                            | ?                   | ?                 | ?                               | ?                     | ?                                | ?                            | ?                    | ?                            | ?                               |



# NMA certainty in evidence

## Elements of a **GRADE** SoF table

### Probiotics compared to no probiotics in INFANTS for the prevention of allergies

**Patient or population:** INFANTS for the prevention of allergies

**Setting:** outpatient

**Intervention:** probiotics

**Comparison:** no probiotics

| Outcomes                                                          | Anticipated absolute effects* (95% CI) |                                        | Relative effect (95% CI)         | N <sub>e</sub> of participants (studies) | Certainty of the evidence (GRADE) |
|-------------------------------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------|------------------------------------------|-----------------------------------|
|                                                                   | Risk with no probiotics                | Risk with probiotics                   |                                  |                                          |                                   |
| Asthma / wheezing - infants<br>follow up: range 6 to 24 months to | 121 per 1,000                          | <b>126 per 1,000</b><br>(76 to 206)    | <b>RR 1.04</b><br>(0.63 to 1.70) | 412<br>(3 RCTs)                          | ⊕○○○<br>VERY LOW<br>a,b,c         |
| Adverse effects<br>follow up: range 6 to 24 months to             | 532 per 1,000                          | <b>676 per 1,000</b><br>(271 to 1,000) | <b>RR 1.27</b><br>(0.51 to 3.18) | 187<br>(2 RCTs)                          | ⊕○○○<br>VERY LOW<br>b,c,d         |

\*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group (and its 95% CI).

**CI:** Confidence interval; **RR:** Risk ratio; **SMD:** Standardised mean difference

# نکات کلی:

- ❑ وجود چندین مداخله برای یک پیامد / یا چند پیامد
- ❑ بسیاری از متاآنالیزهای شبکه ای با همان روش دو به دو تحلیل شده اند
- ❑ تحلیل زیر گروه وجود ندارد اما می توان شبکه های مختلف در تحلیل داشت (subset)
- ❑ تحلیل زیر گروهها ابزار قدرتمند متاآنالیز برای کشف علل هتروژنیته است
- ❑ نرم افزارهای مختلف خروجی های گاه متفاوت دارند
- ❑ با متاآنالیز شبکه ای ضرورت انجام متاآنالیزهای کلاسیک دو به دو کمتر می شود
- ❑ ضرورت انجام مطالعات مختلف با سوال مشترک جهت سنجش اعتبار نتایج

# دو محقق برجسته در زمینه متاآنالیز شبکه ای:



**Prof. Dr. Georgia Salanti**

Head of Research Group, Institute of Social and Preventive Medicine (ISPM)

Phone +41 31 684 33 21

E-Mail [georgia.salanti@unibe.ch](mailto:georgia.salanti@unibe.ch)



**Guido Schwarzer**

PhD, Master of Statistics · Senior Researcher at Faculty of Medicine and Medical Center - University of Freiburg  
Germany

Mohammad Heidari , Ph.D in  
Epidemiology, Urmia University of  
Medical Sciences

## PLOS ONE

OPEN ACCESS PEER-REVIEWED

RESEARCH ARTICLE

### Graphical Tools for Network Meta-Analysis in STATA


Anna Chaimani, Julian P. T. Higgins, Dimitris Mavridis, Panagioti Spyridonos, Georgia Salanti

Published: October 3, 2013 • <https://doi.org/10.1371/journal.pone.0076654>

| Article                  | Authors | Metrics | Comments | Media Coverage |
|--------------------------|---------|---------|----------|----------------|
| <a href="#">Abstract</a> |         |         |          |                |
| Introduction             |         |         |          |                |
| Materials and Methods    |         |         |          |                |
| Results and Discussion   |         |         |          |                |

#### Abstract

Network meta-analysis synthesizes direct and indirect evidence in a network of trials that compare multiple interventions and has the potential to rank the competing treatments according to the studied outcome. Despite its usefulness network meta-analysis is often criticized for its complexity and for being accessible only to researchers with strong statistical



# ابزارهای آنالاین:

CRSU Software Suite (<http://www.nihrcrsu.org/guidance/apps/#d.en.581059>)

- MetaInsight : <https://crsu.shinyapps.io/metainsightc/>

Apps for carrying out network meta-analysis

Owen, RK, Bradbury, N, Xin, Y, Cooper, N, Sutton, A. MetaInsight: An interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta. Res Syn Meth. 2019; 1- 13. <https://doi.org/10.1002/jrsm.1373>

- MetaDTA : [https://crsu.shinyapps.io/dta\\_ma/](https://crsu.shinyapps.io/dta_ma/)

App for carrying out diagnostic test accuracy meta-analysis

Freeman SC, Kerby CR, Patel A, Cooper NJ, Quinn T, Sutton AJ. Development of an interactive web-based tool to conduct and interrogate meta-analysis of diagnostic test accuracy studies: MetaDTA. BMC Medical Research Methodology 2019; 19: 81 <https://doi.org/10.1186/s12874-019-0724-x>

- Primers on diagnostic test evaluation methods: <https://crsu.shinyapps.io/diagprimer/>  
& <https://vigorous-hawking-f95f83.netlify.com/>

Mohammad Heidari , Ph.D in  
Epidemiology, Urmia University of  
Medical Sciences

# ممنون از توجه شما